Nasir Ali Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nasir Ali Shah has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Blake J. Cochran
School of Biomedical Sciences, Faculty of Medicine & Health, UNSW Sydney, Sydney, New South Wales, Australia
4 shared publications - Jonathan H. Erlich
University of New South Wales
4 shared publications Tracie J. Barber
4 shared publicationsZoltan H. Endre
4 shared publicationsBlake J. Cochran
3 shared publicationsJonathan H. Erlich
3 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Elsevier in Kidney Medicine
- Vol. 8 (12)
The Proof is in the Peptide: Baseline NT-proBNP and Cardiac Output Responses at AVF Maturation in Hemodialysis Patients
- 14 October 2026
- Published by Elsevier in Kidney Medicine
- Vol. 8 (12)
Open AccessThe Proof is in the Peptide: Baseline NT-proBNP and Cardiac Output Responses at AVF Maturation in Hemodialysis Patients
- 21 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (14) , e049901
Shear Difference: Flow Type Dictates Endothelial Flow‐Responsive Gene Programs in a 3‐Dimensional–Printed In Vitro Model
Background: Endothelial cells are mechanosensitive and adopt distinct phenotypes in response to hemodynamic forces. These responses are difficult to study in conventional in vitro platforms, which rarely reproduce vessel‐scale geometry or clinically relevant flow. Our aim was to determine how flow impacts endothelial morphology and transcriptional activity in a 3‐dimensional macrofluidic model. Methods: Idealized vessels were 3‐dimensional printed using a water‐soluble polyvinyl alcohol and cast in polydimethylsiloxane. After core dissolution, human microvascular endothelial cell line‐1 cells were grown on the lumen and perfused for 24 hours under static, continuous, or pulsatile flow. The pulsatile waveform was derived from arteriovenous fistula Doppler profiles and scaled to match mean volumetric flow (~100 mL/min) and time‐averaged wall shear stress (~1.5 dyn/cm 2 ) to continuous flow. Morphology was assessed using immunofluorescence. Bulk RNA‐sequencing and gene set enrichment analysis were performed. Results: Relative to static culture, continuous flow increased cell eccentricity (0.74 versus 0.48; P P <0.0001). Differential gene expression was extensive (continuous versus static: 2103 genes; pulsatile versus static: 2643 genes; pulsatile versus continuous: 384 genes). Continuous flow reduced interferon signaling and the Hallmark inflammatory response program relative to static, whereas tumor necrosis factor‐α/nuclear factor‐κ–light‐chain enhancer of activated B cells signaling was increased. Under matched mean shear, pulsatile flow enriched cell cycle/checkpoint programs. Conversely, continuous flow enriched oxidative phosphorylation and p53 pathways. Transforming growth factor‐β signaling was enriched in pulsatile flow. Conclusions: Under matched mean shear, pulsatile and continuous flow were associated with distinct endothelial morphologic and transcriptional signatures. This macrofluidic platform provides a validated, waveform‐controlled testbed for mechanistic and translational studies.
- 21 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (14) , e049901
Shear Difference: Flow Type Dictates Endothelial Flow‐Responsive Gene Programs in a 3‐Dimensional–Printed In Vitro Model
Background: Endothelial cells are mechanosensitive and adopt distinct phenotypes in response to hemodynamic forces. These responses are difficult to study in conventional in vitro platforms, which rarely reproduce vessel‐scale geometry or clinically relevant flow. Our aim was to determine how flow impacts endothelial morphology and transcriptional activity in a 3‐dimensional macrofluidic model. Methods: Idealized vessels were 3‐dimensional printed using a water‐soluble polyvinyl alcohol and cast in polydimethylsiloxane. After core dissolution, human microvascular endothelial cell line‐1 cells were grown on the lumen and perfused for 24 hours under static, continuous, or pulsatile flow. The pulsatile waveform was derived from arteriovenous fistula Doppler profiles and scaled to match mean volumetric flow (~100 mL/min) and time‐averaged wall shear stress (~1.5 dyn/cm 2 ) to continuous flow. Morphology was assessed using immunofluorescence. Bulk RNA‐sequencing and gene set enrichment analysis were performed. Results: Relative to static culture, continuous flow increased cell eccentricity (0.74 versus 0.48; P P <0.0001). Differential gene expression was extensive (continuous versus static: 2103 genes; pulsatile versus static: 2643 genes; pulsatile versus continuous: 384 genes). Continuous flow reduced interferon signaling and the Hallmark inflammatory response program relative to static, whereas tumor necrosis factor‐α/nuclear factor‐κ–light‐chain enhancer of activated B cells signaling was increased. Under matched mean shear, pulsatile flow enriched cell cycle/checkpoint programs. Conversely, continuous flow enriched oxidative phosphorylation and p53 pathways. Transforming growth factor‐β signaling was enriched in pulsatile flow. Conclusions: Under matched mean shear, pulsatile and continuous flow were associated with distinct endothelial morphologic and transcriptional signatures. This macrofluidic platform provides a validated, waveform‐controlled testbed for mechanistic and translational studies.
- Open Access
- 17 July 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (10) , 2202-2218
Seq-ing the Truth
Key Points: Baseline vein single-nucleus RNA sequencing identified molecular programs associated with arteriovenous fistula nonmaturation. Failed arteriovenous fistulas showed endothelial interferon and TNF/NF-κB inflammatory signaling. Failed arteriovenous fistulas showed reduced smooth muscle bioenergetic and proliferative programs. Background: Arteriovenous fistula (AVF) nonmaturation remains common. Although attention has historically focused on postoperative processes, evidence suggests that preanastomotic vessel wall signaling, at AVF creation, contributes to subsequent AVF outcomes. The objective was to integrate quantitative baseline biochemistry and vein histology with single-nucleus RNA sequencing (snRNA-seq) from intraoperative tissue and relate structural, cellular, and molecular features to subsequent AVF maturation. Methods: In a prospective, single-center, observational cohort, 17 consecutive patients undergoing first AVF creation contributed venous tissue for snRNA-seq. Maturation was adjudicated using clinical and/or ultrasound criteria. snRNA-seq used donor-level pseudobulk differential expression within annotated cell types with preranked Hallmark pathway enrichment; serum IL-6 (where available) was included. Results: Nine AVFs matured, and eight failed to mature. Histologic intima–media thickness did not differ by outcome. An intact endothelial layer was more frequent in matured AVFs but did not reach significance (78% versus 25%; P = 0.06). Serum IL-6 did not differ ( P = 0.69). Brachial artery flow at assessment was markedly higher in matured AVFs (mean 973 versus 146 ml/min; P < 0.001). Endothelial cells from failed-to-mature AVFs showed strong enrichment of iIFN- α / γ responses and TNF α /NF-κB signaling (false discovery rate α /NF-κB signaling. Conclusions: Baseline vessel-wall transcriptomes were associated with endothelial inflammatory priming and reduced vascular smooth muscle bioenergetic/proliferative programs in AVFs that subsequently failed to mature. This may inform early risk stratification.
- 17 July 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (10) , 2202-2218
Open AccessSeq-ing the Truth
Key Points: Baseline vein single-nucleus RNA sequencing identified molecular programs associated with arteriovenous fistula nonmaturation. Failed arteriovenous fistulas showed endothelial interferon and TNF/NF-κB inflammatory signaling. Failed arteriovenous fistulas showed reduced smooth muscle bioenergetic and proliferative programs. Background: Arteriovenous fistula (AVF) nonmaturation remains common. Although attention has historically focused on postoperative processes, evidence suggests that preanastomotic vessel wall signaling, at AVF creation, contributes to subsequent AVF outcomes. The objective was to integrate quantitative baseline biochemistry and vein histology with single-nucleus RNA sequencing (snRNA-seq) from intraoperative tissue and relate structural, cellular, and molecular features to subsequent AVF maturation. Methods: In a prospective, single-center, observational cohort, 17 consecutive patients undergoing first AVF creation contributed venous tissue for snRNA-seq. Maturation was adjudicated using clinical and/or ultrasound criteria. snRNA-seq used donor-level pseudobulk differential expression within annotated cell types with preranked Hallmark pathway enrichment; serum IL-6 (where available) was included. Results: Nine AVFs matured, and eight failed to mature. Histologic intima–media thickness did not differ by outcome. An intact endothelial layer was more frequent in matured AVFs but did not reach significance (78% versus 25%; P = 0.06). Serum IL-6 did not differ ( P = 0.69). Brachial artery flow at assessment was markedly higher in matured AVFs (mean 973 versus 146 ml/min; P < 0.001). Endothelial cells from failed-to-mature AVFs showed strong enrichment of iIFN- α / γ responses and TNF α /NF-κB signaling (false discovery rate α /NF-κB signaling. Conclusions: Baseline vessel-wall transcriptomes were associated with endothelial inflammatory priming and reduced vascular smooth muscle bioenergetic/proliferative programs in AVFs that subsequently failed to mature. This may inform early risk stratification.
- Open Access
- 2 June 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (8) , 1772-1780
A Dose of Perspective
Key Points: Both patients and clinicians were broadly supportive of combination therapy in CKD. Implementation remains the main challenge, especially how to start and sequence drugs. Background: CKD affects approximately 15% of adults and remains a major cause of kidney failure and cardiovascular events. Several newer drug classes—sodium-glucose cotransporter 2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, glucagon-like peptide-1 receptor agonists, and endothelin receptor antagonists—provide additional kidney and cardiovascular protection added to standard-of-care renin-angiotensin system inhibition, but the real-world acceptability of using these agents in combination is uncertain. To evaluate the willingness of people with CKD and clinicians to use multidrug combination therapy and to characterize perceived benefits, risks, and barriers to implementation. Methods: We conducted a cross-sectional, descriptive, semiquantitative online survey of adults with CKD and clinicians who prescribe CKD therapies. Parallel questionnaires captured demographics, current treatment, prior experience with multidrug regimens, willingness to receive or prescribe combination therapy, and ranked priorities and concerns. Results: One hundred forty-two people living with CKD and 317 clinicians completed the survey. Most CKD respondents resided in Australia or the United Kingdom; most surveyed clinicians were hospital-based physicians. Willingness to use multiple agents to reduce CKD progression was high (113/142, 80% “yes”; 27/142, 19% “maybe”). Respondents with CKD prioritized reducing CKD progression and preventing complications, while highlighting side effects, long-term safety, and drug-drug interactions as key concerns; pill burden and cost were less frequently prioritized. Clinicians strongly supported combination therapy in a trial context (300/317, 95%) and reported basing prescribing on guideline recommendations, trial evidence, kidney function, and albuminuria. Principal barriers were risks of hyperkalemia and acute eGFR decline, intensified biochemical monitoring, and cost/limited access. Most clinicians preferred staggered rather than simultaneous initiation, typically starting with a sodium-glucose cotransporter 2 inhibitor as the first add-on to background renin-angiotensin system inhibitor therapy. Conclusions: People with CKD and clinicians support multidrug combination therapy, but concerns regarding safety, monitoring burden, and affordability must be addressed to enable routine implementation and large-scale trials.
- 2 June 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (8) , 1772-1780
Open AccessA Dose of Perspective
Key Points: Both patients and clinicians were broadly supportive of combination therapy in CKD. Implementation remains the main challenge, especially how to start and sequence drugs. Background: CKD affects approximately 15% of adults and remains a major cause of kidney failure and cardiovascular events. Several newer drug classes—sodium-glucose cotransporter 2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, glucagon-like peptide-1 receptor agonists, and endothelin receptor antagonists—provide additional kidney and cardiovascular protection added to standard-of-care renin-angiotensin system inhibition, but the real-world acceptability of using these agents in combination is uncertain. To evaluate the willingness of people with CKD and clinicians to use multidrug combination therapy and to characterize perceived benefits, risks, and barriers to implementation. Methods: We conducted a cross-sectional, descriptive, semiquantitative online survey of adults with CKD and clinicians who prescribe CKD therapies. Parallel questionnaires captured demographics, current treatment, prior experience with multidrug regimens, willingness to receive or prescribe combination therapy, and ranked priorities and concerns. Results: One hundred forty-two people living with CKD and 317 clinicians completed the survey. Most CKD respondents resided in Australia or the United Kingdom; most surveyed clinicians were hospital-based physicians. Willingness to use multiple agents to reduce CKD progression was high (113/142, 80% “yes”; 27/142, 19% “maybe”). Respondents with CKD prioritized reducing CKD progression and preventing complications, while highlighting side effects, long-term safety, and drug-drug interactions as key concerns; pill burden and cost were less frequently prioritized. Clinicians strongly supported combination therapy in a trial context (300/317, 95%) and reported basing prescribing on guideline recommendations, trial evidence, kidney function, and albuminuria. Principal barriers were risks of hyperkalemia and acute eGFR decline, intensified biochemical monitoring, and cost/limited access. Most clinicians preferred staggered rather than simultaneous initiation, typically starting with a sodium-glucose cotransporter 2 inhibitor as the first add-on to background renin-angiotensin system inhibitor therapy. Conclusions: People with CKD and clinicians support multidrug combination therapy, but concerns regarding safety, monitoring burden, and affordability must be addressed to enable routine implementation and large-scale trials.
- Open Access
- 7 May 2026
- Published by Springer Nature in Cardiovascular Engineering and Technology
- Vol. 17 (4) , 1-17
A Vein Attempt? Experimental Models for Arteriovenous Fistula Research
Background: Chronic kidney disease (CKD) affects more than 10% of adults worldwide and is associated with rising mortality and increasing demand for hemodialysis. Hemodialysis requires durable vascular access, with surgically created arteriovenous fistulas (AVFs) being the preferred modality. However, up to 60% of AVFs fail to mature in time for clinical use, whereas others develop excessively high flow that can drive adverse cardiac remodeling and heart failure. These problems reflect incomplete understanding of the biological and biomechanical processes that govern AVF maturation and failure. Aim: To summarize the experimental models currently used to study AVF maturation and failure—including animal models, computational approaches and in vitro flow systems—and to compare their respective strengths, limitations and complementary roles in vascular access research. Summary: AVF maturation depends on coordinated arterial and venous remodeling in response to abrupt hemodynamic changes after anastomosis. Altered wall shear stress, pressure and cyclic strain activate endothelial and vascular smooth muscle signaling pathways that promote vasodilation, outward remodeling, matrix turnover and wall thickening. When these adaptive responses are blunted or dysregulated, neointimal hyperplasia, stenosis and access failure ensue. These biomechanical stimuli act within a pro-inflammatory, pro-oxidant uremic milieu, in which circulating toxins impair endothelial function, enhance oxidative stress and bias remodeling towards maladaptation. A broad spectrum of experimental platforms has been developed to interrogate these processes: animal models that recapitulate whole-organism physiology, computational models, including computational fluid dynamics and emerging fluid–structure interaction simulations, that resolve local hemodynamics and wall mechanics; conventional in vitro systems for controlled mechanobiology studies; and emerging microfluidic and macrofluidic devices that impose defined shear waveforms in physiologically relevant geometries. Each model captures selected spatial, temporal or biochemical dimensions of AVF biology, but each is constrained by trade-offs in scalability, fidelity, throughput or translational relevance. Conclusion: AVF maturation and failure arise from tightly coupled biomechanical and biological interactions, shaped by hemodynamic forces and uremia-related vascular dysfunction. No single experimental platform can encompass this complexity. Progress will depend on systematic comparison of available models and their deliberate integration into a coherent multimodal framework, in which insights from animal studies, computational simulations and in vitro flow systems are used in a complementary manner. Such an approach is essential to identify predictive biomarkers, clarify mechanisms of maladaptive remodeling and guide the rational design of targeted interventions to improve AVF patency and clinical outcomes.
- 7 May 2026
- Published by Springer Nature in Cardiovascular Engineering and Technology
- Vol. 17 (4) , 1-17
Open AccessA Vein Attempt? Experimental Models for Arteriovenous Fistula Research
Background: Chronic kidney disease (CKD) affects more than 10% of adults worldwide and is associated with rising mortality and increasing demand for hemodialysis. Hemodialysis requires durable vascular access, with surgically created arteriovenous fistulas (AVFs) being the preferred modality. However, up to 60% of AVFs fail to mature in time for clinical use, whereas others develop excessively high flow that can drive adverse cardiac remodeling and heart failure. These problems reflect incomplete understanding of the biological and biomechanical processes that govern AVF maturation and failure. Aim: To summarize the experimental models currently used to study AVF maturation and failure—including animal models, computational approaches and in vitro flow systems—and to compare their respective strengths, limitations and complementary roles in vascular access research. Summary: AVF maturation depends on coordinated arterial and venous remodeling in response to abrupt hemodynamic changes after anastomosis. Altered wall shear stress, pressure and cyclic strain activate endothelial and vascular smooth muscle signaling pathways that promote vasodilation, outward remodeling, matrix turnover and wall thickening. When these adaptive responses are blunted or dysregulated, neointimal hyperplasia, stenosis and access failure ensue. These biomechanical stimuli act within a pro-inflammatory, pro-oxidant uremic milieu, in which circulating toxins impair endothelial function, enhance oxidative stress and bias remodeling towards maladaptation. A broad spectrum of experimental platforms has been developed to interrogate these processes: animal models that recapitulate whole-organism physiology, computational models, including computational fluid dynamics and emerging fluid–structure interaction simulations, that resolve local hemodynamics and wall mechanics; conventional in vitro systems for controlled mechanobiology studies; and emerging microfluidic and macrofluidic devices that impose defined shear waveforms in physiologically relevant geometries. Each model captures selected spatial, temporal or biochemical dimensions of AVF biology, but each is constrained by trade-offs in scalability, fidelity, throughput or translational relevance. Conclusion: AVF maturation and failure arise from tightly coupled biomechanical and biological interactions, shaped by hemodynamic forces and uremia-related vascular dysfunction. No single experimental platform can encompass this complexity. Progress will depend on systematic comparison of available models and their deliberate integration into a coherent multimodal framework, in which insights from animal studies, computational simulations and in vitro flow systems are used in a complementary manner. Such an approach is essential to identify predictive biomarkers, clarify mechanisms of maladaptive remodeling and guide the rational design of targeted interventions to improve AVF patency and clinical outcomes.
- 10 January 2026
- Published by Wiley in Internal Medicine Journal
- Vol. 56 (1) , 140-141
‘Shroom’ for concern: a case of psychedelic mushroom‐induced acute kidney injury
- 10 January 2026
- Published by Wiley in Internal Medicine Journal
- Vol. 56 (1) , 140-141
‘Shroom’ for concern: a case of psychedelic mushroom‐induced acute kidney injury
- Open Access
- 17 July 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-9
A change of heart: the effect of high flow arteriovenous fistulas on cardiovascular outcomes - a systematic review and synthesis without meta-analysis (SWiM)
Although arteriovenous fistulas (AVF) are widely accepted as the gold standard form of dialysis access for haemodialysis patients, high AVF flow may impose significant haemodynamic stress, potentially contributing to adverse cardiovascular events, including heart failure (HF). We hypothesize that higher AVF flow is associated with adverse cardiovascular outcomes including an increased incidence of heart failure. We sought to clarify this relationship as understanding this association is crucial for improving patient care. A comprehensive search of the PubMed, EMBASE, and Cochrane databases was used to identify observational studies and randomized controlled trials reporting an effect of AVF flow on cardiac outcomes (clinical, echocardiographic, and biomarker). Due to study heterogeneity, meta-analysis was not feasible. Synthesis without meta-analysis (SWiM) was performed using vote counting of direction of effect as the primary outcome. Higher AVF flow rates were consistently associated with increased incidence of HF and worsening HF symptoms. Cardiac imaging revealed left ventricular dilation and reduced left ventricular ejection fraction in patients with high-flow AVFs. Elevated biomarkers, such as natriuretic peptides, corroborated the adverse cardiovascular effects of high AVF flow. This systematic review and synthesis without meta-analysis showed a positive relationship between AVF flow and clinical, echocardiographic, and biomarker cardiovascular outcomes. The methodological heterogeneity of studies highlights the need for well-designed prospective research with standardised definitions of high flow AVFs and measures for reporting of cardiovascular outcomes.
- 17 July 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-9
Open AccessA change of heart: the effect of high flow arteriovenous fistulas on cardiovascular outcomes - a systematic review and synthesis without meta-analysis (SWiM)
Although arteriovenous fistulas (AVF) are widely accepted as the gold standard form of dialysis access for haemodialysis patients, high AVF flow may impose significant haemodynamic stress, potentially contributing to adverse cardiovascular events, including heart failure (HF). We hypothesize that higher AVF flow is associated with adverse cardiovascular outcomes including an increased incidence of heart failure. We sought to clarify this relationship as understanding this association is crucial for improving patient care. A comprehensive search of the PubMed, EMBASE, and Cochrane databases was used to identify observational studies and randomized controlled trials reporting an effect of AVF flow on cardiac outcomes (clinical, echocardiographic, and biomarker). Due to study heterogeneity, meta-analysis was not feasible. Synthesis without meta-analysis (SWiM) was performed using vote counting of direction of effect as the primary outcome. Higher AVF flow rates were consistently associated with increased incidence of HF and worsening HF symptoms. Cardiac imaging revealed left ventricular dilation and reduced left ventricular ejection fraction in patients with high-flow AVFs. Elevated biomarkers, such as natriuretic peptides, corroborated the adverse cardiovascular effects of high AVF flow. This systematic review and synthesis without meta-analysis showed a positive relationship between AVF flow and clinical, echocardiographic, and biomarker cardiovascular outcomes. The methodological heterogeneity of studies highlights the need for well-designed prospective research with standardised definitions of high flow AVFs and measures for reporting of cardiovascular outcomes.
- 4 June 2025
- Published by Wiley in Internal Medicine Journal
- Vol. 55 (6) , 882-884
Clearing the air: smoking status in kidney transplantation assessment – a question of risk or equity?
- 4 June 2025
- Published by Wiley in Internal Medicine Journal
- Vol. 55 (6) , 882-884
Clearing the air: smoking status in kidney transplantation assessment – a question of risk or equity?
- Open Access
A Change of Heart: The Effect of High Flow Arteriovenous Fistulas on Cardiovascular Outcomes - a Systematic Review and Synthesis without Meta-analysis (SWiM)
Background: Although arteriovenous fistulas (AVF) are widely accepted as the gold standard form of dialysis access for hemodialysis patients, high AVF flow may impose significant hemodynamic stress, potentially contributing to adverse cardiovascular events, including heart failure (HF). Understanding this relationship is crucial for improving patient care. Aim: To describe the relationship between AVF flow and cardiac outcomes. Methods: A comprehensive search of the PubMed, EMBASE, and Cochrane databases was used to identify observational studies and randomized controlled trials reporting an effect of AVF flow on cardiac outcomes (clinical, echocardiographic, and biomarker). Due to study heterogeneity, meta-analysis was not feasible. Synthesis without meta-analysis (SWiM) was performed using vote counting of direction of effect as the primary outcome. Results: Higher AVF flow rates were consistently associated with increased incidence of HF and worsening HF symptoms. Cardiac imaging revealed left ventricular dilation and reduced left ventricular ejection fraction in patients with high-flow AVFs. Elevated biomarkers, such as natriuretic peptides, corroborated the adverse cardiovascular effects of high AVF flow. Conclusions: This systematic review and synthesis without meta-analysis showed a positive relationship between AVF flow and clinical, echocardiographic, and biomarker cardiovascular outcomes, but an inverse relationship between AVF flow and mortality. The methodological heterogeneity of studies highlights the need for well-designed prospective research with standardised definitions of high flow AVFs and measures for reporting of cardiovascular outcomes.
Open AccessA Change of Heart: The Effect of High Flow Arteriovenous Fistulas on Cardiovascular Outcomes - a Systematic Review and Synthesis without Meta-analysis (SWiM)
Background: Although arteriovenous fistulas (AVF) are widely accepted as the gold standard form of dialysis access for hemodialysis patients, high AVF flow may impose significant hemodynamic stress, potentially contributing to adverse cardiovascular events, including heart failure (HF). Understanding this relationship is crucial for improving patient care. Aim: To describe the relationship between AVF flow and cardiac outcomes. Methods: A comprehensive search of the PubMed, EMBASE, and Cochrane databases was used to identify observational studies and randomized controlled trials reporting an effect of AVF flow on cardiac outcomes (clinical, echocardiographic, and biomarker). Due to study heterogeneity, meta-analysis was not feasible. Synthesis without meta-analysis (SWiM) was performed using vote counting of direction of effect as the primary outcome. Results: Higher AVF flow rates were consistently associated with increased incidence of HF and worsening HF symptoms. Cardiac imaging revealed left ventricular dilation and reduced left ventricular ejection fraction in patients with high-flow AVFs. Elevated biomarkers, such as natriuretic peptides, corroborated the adverse cardiovascular effects of high AVF flow. Conclusions: This systematic review and synthesis without meta-analysis showed a positive relationship between AVF flow and clinical, echocardiographic, and biomarker cardiovascular outcomes, but an inverse relationship between AVF flow and mortality. The methodological heterogeneity of studies highlights the need for well-designed prospective research with standardised definitions of high flow AVFs and measures for reporting of cardiovascular outcomes.
- 2 December 2024
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 81 (3) , 751-758.e8
Predicting high-flow arteriovenous fistulas and cardiac outcomes in hemodialysis patients
- 2 December 2024
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 81 (3) , 751-758.e8
Predicting high-flow arteriovenous fistulas and cardiac outcomes in hemodialysis patients